NIH RECOMBINANT DNA ADVISORY COMMITTEE TERMINATION IS ONE OF THREE OPTIONS UNDER CONSIDERATION BY DIRECTOR VARMUS, SCIENCE POLICY OFFICER TELLS RAC
Termination of the Recombinant DNA Advisory Committee is one of three options under consideration by National Institutes of Health Director Harold Varmus, MD, regarding the future of the panel, NIH Deputy Director for Science Policy Lana Skirboll reported at the Dec. 4 RAC meeting in Bethesda, Md.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth